Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25364884 | 1.00 | PIK3CD (0.37) | PIK3CDKCNH2HRH3ADRA1AKDR | |
| SCHEMBL25366048 | 0.93 | TLR9 (0.37) | PIK3CDKDRTGFBR1MAPK14PIK3CA | |
| SCHEMBL30557367 | 0.91 | HRH3 (0.41) | PIK3CDKCNH2HRH3ADRA1APIK3CA | |
| SCHEMBL25364915 | 0.91 | HRH3 (0.41) | PIK3CDKCNH2HRH3ADRA1APIK3CA | |
| SCHEMBL30557395 | 0.89 | PIK3CD (0.37) | PIK3CDKCNH2HRH3ADRA1AKDR | |
| SCHEMBL25365611 | 0.89 | PIK3CD (0.37) | PIK3CDKCNH2HRH3ADRA1AKDR | |
| SCHEMBL30557452 | 0.86 | PIK3CD (0.38) | PIK3CDKDRTGFBR1MAPK14PIK3CA | |
| SCHEMBL25364832 | 0.86 | PIK3CD (0.38) | PIK3CDKCNH2HRH3ADRA1AKDR | |
| SCHEMBL25365737 | 0.86 | PIK3CD (0.38) | PIK3CDKDRTGFBR1MAPK14PIK3CA | |
| SCHEMBL30557393 | 0.86 | PIK3CD (0.38) | PIK3CDKCNH2HRH3ADRA1AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479135-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | claimed |
| CN-118786130-A | Substituted imidazopyridinyl compounds useful as TLR9 inhibitors | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2023159154-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | claimed |
| EP-4479135-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118786130-A | Substituted imidazopyridinyl compounds useful as TLR9 inhibitors | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2023159154-A9 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2023159154-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |